statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended March 31, 2024, on Wednesday, May 15, 2024, after the market...

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024

Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria submitted to the 2024...

Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress

Rocky Mountain Advisers LLC trimmed its holdings in shares of Omeros Co. (NASDAQ:OMER - Free Report) by 20.0% in the fourth quarter, according to its most recent filing with the Securities and...

Rocky Mountain Advisers LLC Has $88,000 Stake in Omeros Co. (NASDAQ:OMER)

StockNews.com upgraded shares of Omeros (NASDAQ:OMER - Free Report) from a sell rating to a hold rating in a report published on Wednesday.
Omeros Price Performance
Omeros stock opened at $3.15 on...

Omeros (NASDAQ:OMER) Upgraded by StockNews.com to Hold

Q4 2023 Omeros Corp Earnings Call Transcript

Investors considering a purchase of Omeros Corp (OMER) stock, but tentative about paying the going market price of 3.02/share, might benefit from considering selling puts among the alternative...

Commit To Purchase Omeros At $2, Earn 25.2% Annualized Using Options

Reduced Net Loss and Strategic Developments Mark Omeros Corp's Year-End FinancialsRelated Stocks: OMER...

Omeros Corp (OMER) Reports Fourth Quarter and Year-End 2023 Financial Results

Omeros GAAP EPS of -$0.63 misses by $0.07...

Omeros GAAP EPS of -$0.63 misses by $0.07

Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and...

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Omeros options imply 9.4% move in share price post-earnings

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Watchers	9,199
52-Wk Low	$0.92
52-Wk High	$7.80

Volume	89,761.00
52-Wk High	$7.80
52-Wk Low	$0.92

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.56	--	--	N/A
Q4'23	-$0.15	-$0.15	--	EXPECTED
Q3'23	-$0.61	-$0.60	2.30%	BEAT
Q2'23	-$0.57	-$0.59	-3.51%	MISSED
Q1'23	-$0.53	-$0.54	-1.87%	MISSED

OMER Omeros Corporation

About

Feed

News

Sentiment

Earnings

Fundamentals